MedTrace Logo

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

NCT02637999 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-04-13

Study results available
· View outcomes & findings →

Summary

Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta virus (HDV).

Conditions

  • Chronic Hepatitis D Infection

Interventions

DRUG

PEG IFN alfa-2a

DRUG

Myrcludex B

Sponsors & Collaborators

  • Hepatera Ltd.

    lead INDUSTRY

Principal Investigators

  • Pavel Bogomolov, PhD · LLC "Clinical Hospital of Tsentrosoyuz"

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-13
Primary Completion
2016-01-21
Completion
2016-01-21

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02637999 on ClinicalTrials.gov